Dipraglurant IR is under clinical development by Addex Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dipraglurant IR’s likelihood of approval (LoA) and phase transition for Blepharospasm took place on 31 May 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dipraglurant IR Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dipraglurant IR overview

Dipraglurant IR (ADX-48621) is under development for the treatment of blepharospasm. The drug candidate is administered orally. It is an immediate release formulation. It inhibits the metabotropic glutamate receptor 5 (mGluR5). The drug candidate is based on allosteric modulator discovery technology platform. It was under development for levodopa induced dyskinesia in Parkinson's disease (PD-LID).

Addex Therapeutics overview

Addex Therapeutics (ADDEX) is a clinical-stage pharmaceutical company that discovers, develops and commercializes small-molecule pharmaceutical products, including allosteric modulators for neurological disorders. The company develops its proprietary clinical and preclinical-stage drug candidates using its allosteric modulator drug discovery platform. ADDEX‘s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) intended to treat Parkinson’s disease levodopa-induced dyskinesia. It also carries out clinical and preclinical programs for various indications such as dystonia, epilepsy, post-traumatic stress disorder, Schizophrenia, Other Psychosis, addiction and mild neurocognitive and neurodegenerative disorders. The company has collaboration with Janssen Pharmaceuticals, Indivior PLC, government organizations and other academic researchers. ADDEX is headquartered in Geneva, Switzerland.

Quick View Dipraglurant IR LOA Data

Report Segments
  • Innovator
Drug Name
  • Dipraglurant IR
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.